Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment

Molecular Therapy Nucleic Acids

Volumn 1, Issue 8, 2012, Pages e38-

  Betts, Corinne ^a   Saleh, Amer F ^b   Arzumanov, Andrey A ^b   Hammond, Suzan M ^a   Godfrey, Caroline ^a   Coursindel, Thibault ^b   Gait, Michael J ^b   Wood, Matthew Ja ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Antisense oligonucleotide; Cardiac muscle; Duchenne muscular dystrophy; Phosphorodiamidate morpholino oligomer; PMO internalizing peptide

Indexed keywords

EID: 84868371403     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.30     Document Type: Article

References (41)

1. Emery, AE (1991). Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1: 19-29.
2. Wilton, SD, Lloyd, F, Carville, K, Fletcher, S, Honeyman, K, Agrawal, S et al. (1999). Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9: 330-338. (Pubitemid 29301716)
3. Dunckley, MG, Manoharan, M, Villiet, P, Eperon, IC and Dickson, G (1998). Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7: 1083-1090. (Pubitemid 28306871)
4. Dickson, G, Hill, V and Graham IR (2002). Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul Disord 12 (Suppl 1): S67-S70. (Pubitemid 36158775)
5. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177. (Pubitemid 43214742)
6. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203. (Pubitemid 40094452)
7. Vitiello, L, Bassi, N, Campagnolo, P, Zaccariotto, E, Occhi, G, Malerba, A et al. (2008). In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscul Disord 18: 597-605.
8. van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer- Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
9. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
10. Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
11. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
12. Miller, F, Moseley, CF and Koreska, J (1992). Spinal fusion in Duchenne muscular dystrophy. Dev Med Child Neurol 34: 775-786.
13. English, KM and Gibbs, JL (2006). Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev Med Child Neurol 48: 231-235. (Pubitemid 44404273)
14. Jefferies, JL, Eidem, BW, Belmont, JW, Craigen, WJ, Ware, SM, Fernbach, SD et al. (2005). Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112: 2799-2804. (Pubitemid 41641674)
15. Wu, B, Xiao, B, Cloer, C, Shaban, M, Sali, A, Lu, P et al. (2011). One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther 19: 576-583.
16. Malerba, A, Sharp, PS, Graham, IR, Arechavala-Gomeza, V, Foster, K, Muntoni, F et al. (2011). Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19: 345-354.
17. Malerba, A, Boldrin, L and Dickson, G (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 21: 293-298.
18. Townsend, D, Yasuda, S, Li, S, Chamberlain, JS and Metzger, JM (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16: 832-835. (Pubitemid 351587091)
19. Costas, JM, Nye, DJ, Henley, JB and Plochocki, JH (2010). Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. Muscle Nerve 42: 881-885.
20. Mitchell, DJ, Kim, DT, Steinman, L, Fathman, CG and Rothbard, JB (2000). Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56: 318-325.
21. Abes, R, Arzumanov, A, Moulton, H, Abes, S, Ivanova, G, Gait, MJ et al. (2008). Argininerich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14: 455-460. (Pubitemid 351540906)
22. Abes, R, Moulton, HM, Clair, P, Yang, ST, Abes, S, Melikov, K et al. (2008). Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 36: 6343-6354.
23. Moulton, HM, Fletcher, S, Neuman, BW, McClorey, G, Stein, DA, Abes, S et al. (2007). Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 35(Pt 4): 826-828. (Pubitemid 47310377)
24. Jearawiriyapaisarn, N, Moulton, HM, Sazani, P, Kole, R and Willis, MS (2010). Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 85: 444-453.
25. Wu, B, Moulton, HM, Iversen, PL, Jiang, J, Li, J, Li, J et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105: 14814-14819.
26. Perez, F, Joliot, A, Bloch-Gallego, E, Zahraoui, A, Triller, A and Prochiantz, A (1992). Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 102 (Pt 4): 717-722.
27. Turner, JJ, Ivanova, GD, Verbeure, B, Williams, D, Arzumanov, AA, Abes, S et al. (2005). Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res 33: 6837-6849. (Pubitemid 43000315)
28. Ivanova, GD, Arzumanov, A, Abes, R, Yin, H, Wood, MJ, Lebleu, B et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36: 6418-6428.
29. Yin, H, Saleh, AF, Betts, C, Camelliti, P, Seow, Y, Ashraf, S et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303.
30. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918. (Pubitemid 352762853)
31. Yin, H, Moulton, HM, Betts, C, Seow, Y, Boutilier, J, Iverson, PL et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414.
32. Saleh AF, Arzumanov AA, Yin H, Betts C, Wood MJA and Gait MJ et al. Enhancement of exon skipping and dystrophin production by 3'-peptide conjugates of morpholino (PMO) oligonucleotides in a mdx mouse model of Duchenne muscular dystrophy in Collection Symposium Series, Chemistry of Nucleic Acid Components. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic: Prague, 2011, pp. 292-296.
33. Saleh, AF, Arzumanov, A, Abes, R, Owen, D, Lebleu, B and Gait, MJ (2010). Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem 21: 1902-1911.
34. Arechavala-Gomeza, V, Kinali, M, Feng, L, Brown, SC, Sewry, C, Morgan, JE et al. (2010). Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol 36: 265-274.
35. Malerba, A, Thorogood, FC, Dickson, G and Graham, IR (2009). Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20: 955-965.
36. Gupta, A, Mandal, D, Ahmadibeni, Y, Parang, K and Bothun, G (2011). Hydrophobicity drives the cellular uptake of short cationic peptide ligands. Eur Biophys J 40: 727-736.
37. Thomas, CR, K.E.M.B., Graham, M, Samir, ELA, Caroline, G, Corinne, B et al. (2012). Wood, Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Nucleic Acid Ther.
38. Butterfield, A, Vedagiri, V, Lang, E, Lawrence, C, Wakefield, MJ, Isaev, A et al. (2004). PyEvolve: a toolkit for statistical modelling of molecular evolution. BMC Bioinformatics 5: 1.
39. Brooks, G, Dolphin, M, Vanbeveren, P and Hart, DL (2012). Referral source and outcomes of physical therapy care in patients with low back pain. J Orthop Sports Phys Ther.
40. Bernier, J, Feng, Y and Asakawa, K (2011). Strategies for handling normality assumptions in multi-level modeling: a case study estimating trajectories of Health Utilities Index Mark 3 scores. Health Rep 22: 45-51.
41. Winter, EM, Eston, RG and Lamb, KL (2001). Statistical analyses in the physiology of exercise and kinanthropometry. J Sports Sci 19: 761-775. (Pubitemid 32825577)